体外血液吸附联合VV ECMO治疗重症COVID-19:CytoSorb治疗COVID-19(CTC)注册研究
CTC注册研究为多中心观察性注册(NCT04391920),纳入美国5家学术中心2020年4月至2022年1月ICU中100例需VV ECMO的COVID-19相关ARDS成人,接受体外血液吸附治疗。30天生存率86%、90天生存率74%。以入住ICU至启动吸附中位87小时行事后分组,早期组(≤87 h)较晚期组(>87 h)机械通气、ECMO支持及ICU停留均更短,90天生存率82% vs 66%(p=0.14)未达统计学显著。未报告器械相关不良事件。作者认为结果支持VV ECMO联合血液吸附的「增强肺休息」概念。
要点
- 100例COVID-19相关ARDS行VV ECMO联合血液吸附者,30天生存率86%、90天生存率74%。
- 以入住ICU至启动吸附中位87小时分组:早期组(≤87 h)机械通气7(2-26)天 vs 晚期组17(7-37)天,p=0.02。
- 早期组ECMO支持13(8-24)天 vs 晚期组29(14-38)天,p=0.021;ICU停留17(10-40)天 vs 36(19-55)天,p=0.002。
- 90天生存率早期组82% vs 晚期组66%(p=0.14),未达统计学显著。
- 未报告器械相关不良事件。
适用人群与场景
- 美国5家主要学术中心ICU中,2020年4月至2022年1月收治的100例COVID-19相关ARDS、需VV ECMO支持的危重成人(63%男性,年龄44±11岁)。
- 患者均接受体外血液吸附治疗,注册研究在FDA紧急使用授权下开展。
诊断标准与关键阈值
- 事后按入住ICU至启动血液吸附的中位时间87小时分组:≤87 h为早期启动组(GE),>87 h为晚期启动组(GL)。
研究设计与关键结果
- 多中心、观察性注册研究(NCT04391920),纳入100例COVID-19相关ARDS行VV ECMO联合体外血液吸附的危重成人,主要结局为死亡,采用时间-事件分析。
- 30天生存率86%,90天生存率74%。
- 入住ICU至启动血液吸附中位时间87小时;早期组(≤87 h)vs 晚期组(>87 h):机械通气中位7(2-26)天 vs 17(7-37)天,p=0.02;ECMO支持13(8-24)天 vs 29(14-38)天,p=0.021;ICU停留17(10-40)天 vs 36(19-55)天,p=0.002。
- 90天生存率早期组82% vs 晚期组66%(p=0.14),未达统计学显著。
- 未报告器械相关不良事件。
证据类型、等级与局限
- 证据类型:多中心观察性注册研究(NCT04391920)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在重症COVID-19相关ARDS接受VV ECMO联合血液吸附的患者中,较早干预与更短的器官支持需求和ICU停留相关,结果支持「增强肺休息」概念。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The CytoSorb therapy in COVID-19 (CTC) registry evaluated the clinical performance and treatment parameters of extracorporeal hemoadsorption integrated with veno-venous extracorporeal membrane oxygenation (VV ECMO) in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) and respiratory failure under US FDA Emergency Use Authorization.
DESIGN: Multicenter, observational, registry (NCT04391920).
SETTING: Intensive care units (ICUs) in five major US academic centers between April 2020 and January 2022.
PATIENTS: A total of 100 critically ill adults with COVID-19-related ARDS requiring VV ECMO support, who were treated with extracorporeal hemoadsorption.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Baseline demographics, clinical characteristics, laboratory values and outcomes were recorded following individual ethics committee approval at each center. Detailed data on organ support utilization parameters and hemoadsorption treatments were also collected. Biomarker data were collected according to the standard practice at each participating site, and available values were compared before and after hemoadsorption. The primary outcome of mortality was evaluated using a time-to-event analysis. A total of 100 patients (63% male; age 44 ± 11 years) were included. Survival rates were 86% at 30 days and 74% at 90 days. Median time from ICU admission to the initiation of hemoadsorption was 87 h and was used to define two post hoc groups: ≤ 87 h (group-early start, GE) and > 87 h (group-late start, GL). After the start of hemoadsorption, patients in the GE versus GL had significantly shorter median duration of mechanical ventilation (7 [2-26] vs. 17 [7-37] days, p = 0.02), ECMO support (13 [8-24] vs. 29 [14-38] days, p = 0.021) and ICU stay (17 [10-40] vs 36 [19-55] days, p = 0.002). Survival at 90 days in GE was 82% compared to 66% in GL (p = 0.14). No device-related adverse events were reported.
CONCLUSIONS: In critically ill patients with severe COVID-19-related ARDS treated with the combination of VV-ECMO and hemoadsorption, 90-day survival was 74% and earlier intervention was associated with shorter need for organ support and ICU stay. These results lend support to the concept of "enhanced lung rest" with the combined use of VV-ECMO plus hemoadsorption in patients with ARDS.
参考来源
- Hayanga JWA, Song T, Durham L, et al. Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry. Crit Care. 2023. PMID: 37337243. doi:10.1186/s13054-023-04517-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。